QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=E9E86C02D94947BEC4CC49F65A2950D0;jsessionid=605F090336C62933296D11614CE7E775;jsessionid=88AFA44423A98EB7144772A201DA36F8;jsessionid=B3AAE525278C99D80671FE120977993C;jsessionid=1049FE07599C3EFF0F6DF8ED98EC25A8;jsessionid=8D86541B2F01B86911F52489F322EE04 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. ATXN2 is a target of N-terminal proteolysis.
3. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…
4. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
5. TDP-43 impairs sleep in Drosophila through Ataxin-2-dependent metabolic disturbance.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=47BD8608FF341F1D3328BD9EEC561979;jsessionid=A043B438A3B5591667B8740B38982408;jsessionid=E9E86C02D94947BEC4CC49F65A2950D0;jsessionid=605F090336C62933296D11614CE7E775;jsessionid=88AFA44423A98EB7144772A201DA36F8;jsessionid=B3AAE525278C99D80671FE120977993C;jsessionid=1049FE07599C3EFF0F6DF8ED98EC25A8;jsessionid=8D86541B2F01B86911F52489F322EE04